# US 2024/0252483 A1 · Gastric residence systems comprising buprenorphine and naloxone

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0252483 A1
- Document ID: US20240252483A1
- Status: Published application
- Kind: A1
- Application number: 18/289,331
- Filed: 2022-05-04
- Published: 2024-08-01
- Earliest claimed: 2021-05-05
- Assignees: Lyndra Therapeutics, Inc.
- Applicants: Lyndra Therapeutics, Inc.
- Inventors: Nupura BHISE; Jeffrey KATSTRA; David ALTREUTER
- Web page: https://patentgrep.com/patent/US20240252483A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 9/0065: {Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/284: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 9/2072: {characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K9/0004, A61K9/0056, A61K9/0065 take precedence)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided are gastric residence systems comprising at least one co-extruded drug-eluting component comprising a carrier polymer, buprenorphine or a salt thereof, and naloxone or a salt thereof, and a rate-modulating release film coating the at least one co-extruded drug-eluting component. The gastric residence systems comprising at least one co-extruded drug-eluting component are configured to be maintained within a stomach of a human body for at least 48 hours and to release buprenorphine for at least 48 hours, such that the at least one co-extruded drug eluting component with the rate-modulating release film is configured to release at least 10% of the buprenorphine or the salt thereof after the first 24 hours of residence within the stomach and at least 10% of the naloxone or the salt thereof after the first 24 hours of residence within the stomach.

## Claims

### Claim 1

A gastric residence system comprising:
at least one co-extruded drug-eluting component comprising a carrier polymer, buprenorphine or a salt thereof, and naloxone or a salt thereof; and
a rate-modulating release film coating the at least one co-extruded drug-eluting component,
wherein the gastric residence system is configured to be maintained within a stomach of a human body for at least 48 hours and to release buprenorphine for at least 48 hours, and the at least one co-extruded drug eluting component with the rate-modulating release film is configured to release at least 10% of the buprenorphine or the salt thereof after the first 24 hours of residence within the stomach and at least 10% of the naloxone or the salt thereof after the first 24 hours of residence within the stomach.

### Claim 2 (depends on 1)

The gastric residence system of claim 1, wherein the rate-modulating release film comprises polycaprolactone and copovidone.

### Claim 3 (depends on 2)

The gastric residence system of claim 2, wherein the rate-modulating release film comprises 60-90 wt % polycaprolactone.

### Claim 4 (depends on 2, 3)

The gastric residence system of claim 2 or 3, wherein the rate-modulating release film comprises 10-40 wt % copovidone.

### Claim 5 (depends on 1, 2, 3, 4)

The gastric residence system of any of claims 1-4, wherein the at least one co-extruded drug-eluting component comprises a first co-extruded portion comprising naloxone and a second co-extruded portion comprising buprenorphine and naloxone.

### Claim 6 (depends on 5)

The gastric residence system of claim 5, wherein the first co-extruded portion is embedded in the second co-extruded portion.

### Claim 7 (depends on 5, 6)

The gastric residence system of claim 5 or 6, wherein the first co-extruded portion comprises one or more strands that are embedded within the second co-extruded portion.

### Claim 8 (depends on 5)

The gastric residence system of claim 5, wherein the first co-extruded portion is layered on the second co-extruded portion.

### Claim 9 (depends on 5, 6, 7, 8)

The gastric residence system of any of claims 5-8, wherein the first co-extruded portion is present at a ratio of 4:1 to the second co-extruded portion.

### Claim 10 (depends on 5, 6, 7, 8, 9)

The gastric residence system of any of claims 5-9, wherein the first co-extruded portion comprises 35-50 wt % buprenorphine.

### Claim 11 (depends on 5, 6, 7, 8, 9, 10)

The gastric residence system of any of claims 5-10, wherein the first co-extruded portion comprises 2-7 wt % naloxone.

### Claim 12 (depends on 5, 6, 7, 8, 9, 10, 11)

The gastric residence system of any of claims 5-11, wherein the first co-extruded portion comprises 35-50 wt % polycaprolactone.

### Claim 13 (depends on 5, 6, 7, 8, 9, 10, 11, 12)

The gastric residence system of any of claims 5-12, wherein the first co-extruded portion comprises polyethylene glycol and a poloxamer.

### Claim 14 (depends on 5, 6, 7, 8, 9, 10, 11, 12, 13)

The gastric residence system of any of claims 5-13, wherein the second co-extruded portion comprises 30-50 wt % naloxone.

### Claim 15 (depends on 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The gastric residence system of any of claims 5-14, wherein the second co-extruded portion comprises 50-60 wt % polycaprolactone.

### Claim 16 (depends on 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The gastric residence system of any of claims 5-15, wherein the second co-extruded portion comprises poloxamer.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The gastric residence system of any of claims 1-16, wherein the at least one co-extruded drug-eluting component comprises 30 mg to 40 mg of buprenorphine or a salt thereof.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The gastric residence system of any of claims 1-17, wherein the at least one co-extruded drug-eluting component comprises 8 mg to 15 mg of naloxone or a salt thereof.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The gastric residence system of any of claims 1-18, wherein the gastric residence system comprises a central elastomer and a plurality of arms, each arm of the plurality of arms comprising a proximal end affixed to the central elastomer and a distal end, wherein each arm of the plurality of arms extends radially from the central elastomer, and at least one arm of the plurality of arms comprises the at least one co-extruded drug-eluting component.

### Claim 20 (depends on 19)

The gastric residence system of claim 19, wherein the plurality of arms comprises six arms.

### Claim 21 (depends on 19, 20)

The gastric residence system of claim 19 or 20, wherein at least two arms of the plurality of arms comprises a co-extruded drug-eluting component of the at least one co-extruded drug-eluting component.

### Claim 22 (depends on 19, 20)

The gastric residence system of claim 19 or 20, wherein at least three arms of the plurality of arms comprises a co-extruded drug-eluting component of the at least one co-extruded drug-eluting component.

### Claim 23 (depends on 19, 20)

The gastric residence system of claim 19 or 20, wherein six arms of the plurality of arms comprises a co-extruded drug-eluting component of the at least one co-extruded drug-eluting component.

### Claim 24 (depends on 19, 20, 21, 22, 23)

The gastric residence system of any of claims 19-23, wherein each arm of the plurality of arms comprises a polymeric linker segment attached to the central elastomer, the polymeric linker segment comprising polycaprolactone.

### Claim 25 (depends on 24)

The gastric residence system of claim 24, wherein each arm of the plurality of arms comprises a first disintegrating matrix segment attached to the polymeric linker segment, the first disintegrating matrix segment comprising polycaprolactone, an acid terminated copolymer of DL-lactide and glycolide (50/50 molar ratio), a copolymer of DL-lactide and glycolide (50/50 molar ratio), and polyethylene oxide.

### Claim 26 (depends on 25)

The gastric residence system of claim 25, wherein each arm of the plurality of arms comprises a first inert segment attached to the first disintegrating matrix segment, the first inert segment comprising polycaprolactone, and (BiO)2CO3.

### Claim 27 (depends on 26)

The gastric residence system of claim 26, wherein each arm of the plurality of arms comprises a second disintegrating matrix segment attached to the first inert segment, the second disintegrating matrix segment comprising polycaprolactone, hydroxypropyl methylcellulose acetate succinate, and a poloxamer.

### Claim 28 (depends on 27)

The gastric residence system of claim 27, wherein each arm of the plurality of arms comprises a second inert segment attached to the second disintegrating matrix segment, the second inert segment comprising polycaprolactone, and (BiO)2CO3.

### Claim 29 (depends on 28)

The gastric residence system of claim 28, wherein a first arm of the plurality of arms comprises a co-extruded drug-eluting component of the at least one co-extruded drug-eluting component attached to the second inert segment.

### Claim 30 (depends on 28)

The gastric residence system of claim 28, wherein a second arm of the plurality of arms comprises an inactive segment attached to the second inert segment, the inactive segment comprising polycaprolactone, copovidone, and a poloxamer.

### Claim 31 (depends on 29, 30)

The gastric residence system of claim 29 or 30, wherein each arm of the plurality of arms comprises a third inert segment attached to one of the co-extruded drug-eluting component or the inactive segment, the third inert segment comprising polycaprolactone, and (BiO)2CO3.

### Claim 32 (depends on 31)

The gastric residence system of claim 31, wherein each arm of the plurality of arms comprises a third disintegrating matrix segment attached to the third inert segment, the third disintegrating matrix comprising polycaprolactone, hydroxypropyl methylcellulose acetate succinate (HPMCAS); stearic acid; and polypropylene glycol.

### Claim 33 (depends on 32)

The gastric residence system of claim 32, comprising a filament circumferentially connecting each arm, wherein the circumferential filament is attached to the third disintegrating matrix segment of each arm.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

A method of treating an opioid abuse disorder in an individual, comprising administering the gastric residence system of any one of claims 1-33 to the individual.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

A method of treating pain in an individual, comprising administering the gastric residence system of any one of claims 1-33 to the individual.

### Claim 36

A gastric residence system comprising:
at least one drug-eluting component comprising a carrier polymer, buprenorphine or a salt thereof, and naloxone or a salt thereof; and
a rate-modulating release film coating the at least one drug-eluting component,
wherein the gastric residence system is configured to be maintained within a stomach of a human body for at least 48 hours and to release buprenorphine for at least 48 hours, and the at least one drug-eluting component with the rate-modulating release film is configured to release at least 10% of the buprenorphine or the salt thereof after the first 24 hours of residence within the stomach and at least 10% of the naloxone or the salt thereof within the first 24 hours of residence within the stomach.

### Claim 37 (depends on 36)

The gastric residence system of claim 36, wherein the rate-modulating release film comprises polycaprolactone and copovidone.

### Claim 38 (depends on 37)

The gastric residence system of claim 37, wherein the rate-modulating release film comprises 60-90 wt % polycaprolactone.

### Claim 39 (depends on 36, 37)

The gastric residence system of claim 36 or 37, wherein the rate-modulating release film comprises 10-40 wt % copovidone.

### Claim 40 (depends on 36, 37, 38, 39)

The gastric residence system of any of claims 36-39, wherein the at least one drug-eluting component comprises 35-50 wt % buprenorphine.

### Claim 41 (depends on 36, 37, 38, 39, 40)

The gastric residence system of any of claims 36-40, wherein the at least one drug-eluting component comprises 2-7 wt % naloxone.

### Claim 42 (depends on 36, 37, 38, 39, 40, 41)

The gastric residence system of any of claims 36-41, wherein the at least one drug-eluting component comprises 35-50 wt % polycaprolactone.

### Claim 43 (depends on 36, 37, 38, 39, 40, 41, 42)

The gastric residence system of any of claims 36-42, wherein the at least one drug-eluting component comprises polyethylene glycol and a poloxamer.

### Claim 44 (depends on 36, 37, 38, 39, 40, 41, 42, 43)

The gastric residence system of any of claims 36-43, wherein the at least one drug-eluting component comprises 10 mg to 30 mg of buprenorphine or a salt thereof.

### Claim 45 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44)

The gastric residence system of any of claims 36-44, wherein the at least one drug-eluting component comprises 1 mg to 3 mg of naloxone or a salt thereof.

### Claim 46 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The gastric residence system of any of claims 36-45, wherein the gastric residence system comprises a central elastomer and a plurality of arms, each arm of the plurality of arms comprising a proximal end affixed to the central elastomer and a distal end, wherein each arm of the plurality of arms extends radially from the central elastomer, and at least one arm of the plurality of arms comprises the at least one drug-eluting component.

### Claim 47 (depends on 46)

The gastric residence system of claim 46, wherein the plurality of arms comprises six arms.

### Claim 48 (depends on 46, 47)

The gastric residence system of claim 46 or 47, wherein at least two arms of the plurality of arms comprises a drug-eluting component of the at least one drug-eluting component.

### Claim 49 (depends on 46, 47)

The gastric residence system of claim 46 or 47, wherein at least three arms of the plurality of arms comprises a drug-eluting component of the at least one drug-eluting component.

### Claim 50 (depends on 46, 47)

The gastric residence system of claim 46 or 47, wherein six arms of the plurality of arms comprises a drug-eluting component of the at least one drug-eluting component.

### Claim 51 (depends on 46, 47, 48, 49, 50)

The gastric residence system of any of claims 46-50, wherein each arm of the plurality of arms comprises a polymeric linker segment attached to the central elastomer, the polymeric linker segment comprising polycaprolactone.

### Claim 52 (depends on 51)

The gastric residence system of claim 51, wherein each arm of the plurality of arms comprises a first disintegrating matrix segment attached to the polymeric linker segment, the first disintegrating matrix segment comprising polycaprolactone, an acid terminated copolymer of DL-lactide and glycolide (50/50 molar ratio), a copolymer of DL-lactide and glycolide (50/50 molar ratio), and polyethylene oxide.

### Claim 53 (depends on 52)

The gastric residence system of claim 52, wherein each arm of the plurality of arms comprises a first inert segment attached to the first disintegrating matrix segment, the first inert segment comprising polycaprolactone, and (BiO)2CO3.

### Claim 54 (depends on 53)

The gastric residence system of claim 53, wherein each arm of the plurality of arms comprises a second disintegrating matrix segment attached to the first inert segment, the second disintegrating matrix segment comprising polycaprolactone, hydroxypropyl methylcellulose acetate succinate, and a poloxamer.

### Claim 55 (depends on 54)

The gastric residence system of claim 54, wherein each arm of the plurality of arms comprises a second inert segment attached to the second disintegrating matrix segment, the second inert segment comprising polycaprolactone, and (BiO)2CO3.

### Claim 56 (depends on 55)

The gastric residence system of claim 55, wherein a first arm of the plurality of arms comprises a drug-eluting component of the at least one drug-eluting component attached to the second inert segment.

### Claim 57 (depends on 55)

The gastric residence system of claim 55, wherein a second arm of the plurality of arms comprises an inactive segment attached to the second inert segment, the inactive segment comprising polycaprolactone, copovidone, and a poloxamer.

### Claim 58 (depends on 56, 57)

The gastric residence system of claim 56 or 57, wherein each arm of the plurality of arms comprises a third inert segment attached to one of the drug-eluting component or the inactive segment, the third inert segment comprising polycaprolactone, and (BiO)2CO3.

### Claim 59 (depends on 58)

The gastric residence system of claim 58, wherein each arm of the plurality of arms comprises a third disintegrating matrix segment attached to the third inert segment, the third disintegrating matrix comprising polycaprolactone, hydroxypropyl methylcellulose acetate succinate (HPMCAS); stearic acid; and polypropylene glycol.

### Claim 60 (depends on 59)

The gastric residence system of claim 59, comprising a filament circumferentially connecting each arm, wherein the circumferential filament is attached to the third disintegrating matrix segment of each arm.

### Claim 61 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

A method of treating an opioid abuse disorder in an individual, comprising administering the gastric residence system of any one of claims 36-60 to the individual.

### Claim 62 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

A method of treating pain in an individual, comprising administering the gastric residence system of any one of claims 36-60 to the individual.

### Claim 63

A gastric residence system comprising:
a plurality of arms affixed to a central elastomer, wherein at least one arm comprises a drug-eluting component;
each arm comprising a proximal end, a distal end, and an outer surface therebetween; wherein the proximal end of each arm is attached to the elastomer component and projects radially from the elastomer component, each arm having its distal end not attached to the elastomer component and located at a larger radial distance from the elastomer component than the proximal end;
wherein the at least one arm comprising a drug eluting component comprises:
a polymeric linker segment;
a first disintegrating matrix segment attached to the polymeric linker segment;
a first inert segment attached to the first disintegrating matrix segment;
a second disintegrating matrix segment attached to the first inert segment;
a second inert segment attached to the second disintegrating matrix segment;
the drug-eluting component attached to the second inert segment, wherein the drug eluting component comprises a carrier polymer, buprenorphine or a salt thereof, and naloxone or a salt thereof, and wherein the drug eluting component further comprises a coating comprising a release rate-modulating polymer film;
a third inert segment attached to the drug-eluting component;
a third disintegrating matrix segment attached to the third inert segment;
and
a filament circumferentially connecting each arm.

### Claim 64

A method of making a gastric residence system comprising:
co-extruding at least one drug-eluting component comprising a carrier polymer, buprenorphine or a salt thereof, and naloxone or a salt thereof; and
applying a rate-modulating release film to the at least one co-extruded drug-eluting component,
wherein the gastric residence system is configured to be maintained within a stomach of a human body for at least 48 hours and to release buprenorphine for at least 48 hours, and the at least one co-extruded drug eluting component with the rate-modulating release film is configured to release at least 10% of the buprenorphine or the salt thereof after the first 24 hours of residence within the stomach and at least 10% of the naloxone or the salt thereof after the first 24 hours of residence within the stomach.

### Claim 65 (depends on 64)

The method of claim 64, wherein the rate-modulating release film comprises polycaprolactone and copovidone.

### Claim 66 (depends on 65)

The method of claim 65, wherein the rate-modulating release film comprises 60-90 wt % polycaprolactone.

### Claim 67 (depends on 65, 66)

The method of claim 65 or 66, wherein the rate-modulating release film comprises 10-40 wt % copovidone.

### Claim 68 (depends on 64, 65, 66, 67)

The method of any of claims 64-67, wherein the at least one co-extruded drug-eluting component comprises a first co-extruded portion comprising naloxone and a second co-extruded portion comprising buprenorphine and naloxone.

### Claim 69 (depends on 68)

The method of claim 68, wherein co-extruding the at least one drug-eluting component comprises co-extruding the first co-extruded portion embedded in the second co-extruded portion.

### Claim 70 (depends on 68, 69)

The method of claim 68 or 69, wherein co-extruding the at least one drug-eluting component comprises co-extruding strands of the first co-extruded portion embedded within the second co-extruded portion.

### Claim 71 (depends on 68)

The method of claim 68, wherein co-extruding the at least one drug-eluting component comprises co-extruding the first co-extruded portion layered on the second co-extruded portion.

### Claim 72 (depends on 68, 69, 70, 71)

The method of any of claims 68-71, wherein the first co-extruded portion is present at a ratio of 4:1 to the second co-extruded portion.

### Claim 73 (depends on 68, 69, 70, 71, 72)

The method of any of claims 68-72, wherein the first co-extruded portion comprises 35-50 wt % buprenorphine.

### Claim 74 (depends on 68, 69, 70, 71, 72, 73)

The method of any of claims 68-73, wherein the first co-extruded portion comprises 2-7 wt % naloxone.

### Claim 75 (depends on 68, 69, 70, 71, 72, 73, 74)

The method of any of claims 68-74, wherein the first co-extruded portion comprises 35-50 wt % polycaprolactone.

### Claim 76 (depends on 68, 69, 70, 71, 72, 73, 74, 75)

The method of any of claims 68-75, wherein the first co-extruded portion comprises polyethylene glycol and a poloxamer.

### Claim 77 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76)

The method of any of claims 68-76, wherein the second co-extruded portion comprises 30-50 wt % naloxone.

### Claim 78 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The method of any of claims 68-77, wherein the second co-extruded portion comprises 50-60 wt % polycaprolactone.

### Claim 79 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The method of any of claims 68-78, wherein the second co-extruded portion comprises poloxamer.

### Claim 80 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

The method of any of claims 64-79, wherein the at least one co-extruded drug-eluting component comprises 30 mg to 40 mg of buprenorphine or a salt thereof.

### Claim 81 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The method of any of claims 64-80, wherein the at least one co-extruded drug-eluting component comprises 8 mg to 15 mg of naloxone or a salt thereof.

### Claim 82 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The method of any of claims 64-81, wherein the gastric residence system comprises a central elastomer and a plurality of arms, each arm of the plurality of arms comprising a proximal end affixed to the central elastomer and a distal end, wherein each arm of the plurality of arms extends radially from the central elastomer, and at least one arm of the plurality of arms comprises the at least one co-extruded drug-eluting component.

### Claim 83 (depends on 82)

The method of claim 82, wherein the plurality of arms comprises six arms.

### Claim 84 (depends on 82, 83)

The method of claim 82 or 83, wherein at least two arms of the plurality of arms comprises a co-extruded drug-eluting component of the at least one co-extruded drug-eluting component.

### Claim 85 (depends on 82, 83)

The method of claim 82 or 83, wherein at least three arms of the plurality of arms comprises a co-extruded drug-eluting component of the at least one co-extruded drug-eluting component.

### Claim 86 (depends on 82, 83)

The method of claim 82 or 83, wherein six arms of the plurality of arms comprises a co-extruded drug-eluting component of the at least one co-extruded drug-eluting component.

### Claim 87 (depends on 82, 83, 84, 85, 86)

The method of any of claims 82-86, wherein each arm of the plurality of arms comprises a polymeric linker segment attached to the central elastomer, the polymeric linker segment comprising polycaprolactone.

### Claim 88 (depends on 87)

The method of claim 87, wherein each arm of the plurality of arms comprises a first disintegrating matrix segment attached to the polymeric linker segment, the first disintegrating matrix segment comprising polycaprolactone, an acid terminated copolymer of DL-lactide and glycolide (50/50 molar ratio), a copolymer of DL-lactide and glycolide (50/50 molar ratio), and polyethylene oxide.

### Claim 89 (depends on 88)

The method of claim 88, wherein each arm of the plurality of arms comprises a first inert segment attached to the first disintegrating matrix segment, the first inert segment comprising polycaprolactone, and (BiO)2CO3.

### Claim 90 (depends on 89)

The method of claim 89, wherein each arm of the plurality of arms comprises a second disintegrating matrix segment attached to the first inert segment, the second disintegrating matrix segment comprising polycaprolactone, hydroxypropyl methylcellulose acetate succinate, and a poloxamer.

### Claim 91 (depends on 90)

The method of claim 90, wherein each arm of the plurality of arms comprises a second inert segment attached to the second disintegrating matrix segment, the second inert segment comprising polycaprolactone, and (BiO)2CO3.

### Claim 92 (depends on 91)

The method of claim 91, wherein a first arm of the plurality of arms comprises a co-extruded drug-eluting component of the at least one co-extruded drug-eluting component attached to the second inert segment.

### Claim 93 (depends on 91)

The method of claim 91, wherein a second arm of the plurality of arms comprises an inactive segment attached to the second inert segment, the inactive segment comprising polycaprolactone, copovidone, and a poloxamer.

### Claim 94 (depends on 92, 93)

The method of claim 92 or 93, wherein each arm of the plurality of arms comprises a third inert segment attached to one of the co-extruded drug-eluting component or the inactive segment, the third inert segment comprising polycaprolactone, and (BiO)2CO3.

### Claim 95 (depends on 94)

The method of claim 94, wherein each arm of the plurality of arms comprises a third disintegrating matrix segment attached to the third inert segment, the third disintegrating matrix comprising polycaprolactone, hydroxypropyl methylcellulose acetate succinate (HPMCAS); stearic acid; and polypropylene glycol.

### Claim 96 (depends on 95)

The method of claim 95, comprising a filament circumferentially connecting each arm, wherein the circumferential filament is attached to the third disintegrating matrix segment of each arm.

### Claim 97

A method of making a gastric residence system comprising:
extruding at least one drug-eluting component comprising a carrier polymer, buprenorphine or a salt thereof, and naloxone or a salt thereof; and
applying a rate-modulating release film to the at least one drug-eluting component,
wherein the gastric residence system is configured to be maintained within a stomach of a human body for at least 48 hours and to release buprenorphine for at least 48 hours, and the at least one drug-eluting component with the rate-modulating release film is configured to release at least 10% of the buprenorphine or the salt thereof after the first 24 hours of residence within the stomach and at least 10% of the naloxone or the salt thereof within the first 24 hours of residence within the stomach.

### Claim 98 (depends on 97)

The method of claim 97, wherein the rate-modulating release film comprises polycaprolactone and copovidone.

### Claim 99 (depends on 98)

The method of claim 98, wherein the rate-modulating release film comprises 60-90 wt % polycaprolactone.

### Claim 100 (depends on 98, 99)

The method of claim 98 or 99, wherein the rate-modulating release film comprises 10-40 wt % copovidone.

### Claim 101 (depends on 97, 98, 99, 100)

The method of any of claims 97-100, wherein the at least one drug-eluting component comprises 35-50 wt % buprenorphine.

### Claim 102 (depends on 97, 98, 99, 100, 101)

The method of any of claims 97-101, wherein the at least one drug-eluting component comprises 2-7 wt % naloxone.

### Claim 103 (depends on 97, 98, 99, 100, 101, 102)

The method of any of claims 97-102, wherein the at least one drug-eluting component comprises 35-50 wt % polycaprolactone.

### Claim 104 (depends on 97, 98, 99, 100, 101, 102, 103)

The method of any of claims 97-103, wherein the at least one drug-eluting component comprises polyethylene glycol and a poloxamer.

### Claim 105 (depends on 97, 98, 99, 100, 101, 102, 103, 104)

The method of any of claims 97-104, wherein the at least one drug-eluting component comprises 10 mg to 30 mg of buprenorphine or a salt thereof.

### Claim 106 (depends on 97, 98, 99, 100, 101, 102, 103, 104, 105)

The method of any of claims 97-105, wherein the at least one drug-eluting component comprises 1 mg to 3 mg of naloxone or a salt thereof.

### Claim 107 (depends on 97, 98, 99, 100, 101, 102, 103, 104, 105, 106)

The method of any of claims 97-106, wherein the gastric residence system comprises a central elastomer and a plurality of arms, each arm of the plurality of arms comprising a proximal end affixed to the central elastomer and a distal end, wherein each arm of the plurality of arms extends radially from the central elastomer, and at least one arm of the plurality of arms comprises the at least one drug-eluting component.

### Claim 108 (depends on 107)

The method of claim 107, wherein the plurality of arms comprises six arms.

### Claim 109 (depends on 107, 108)

The method of claim 107 or 108, wherein at least two arms of the plurality of arms comprises a drug-eluting component of the at least one drug-eluting component.

### Claim 110 (depends on 107, 108)

The method of claim 107 or 108, wherein at least three arms of the plurality of arms comprises a drug-eluting component of the at least one drug-eluting component.

### Claim 111 (depends on 107, 108)

The method of claim 107 or 108, wherein six arms of the plurality of arms comprises a drug-eluting component of the at least one drug-eluting component.

### Claim 112 (depends on 107, 108, 109, 110, 111)

The method of any of claims 107-111, wherein each arm of the plurality of arms comprises a polymeric linker segment attached to the central elastomer, the polymeric linker segment comprising polycaprolactone.

### Claim 113 (depends on 112)

The method of claim 112, wherein each arm of the plurality of arms comprises a first disintegrating matrix segment attached to the polymeric linker segment, the first disintegrating matrix segment comprising polycaprolactone, an acid terminated copolymer of DL-lactide and glycolide (50/50 molar ratio), a copolymer of DL-lactide and glycolide (50/50 molar ratio), and polyethylene oxide.

### Claim 114 (depends on 113)

The method of claim 113, wherein each arm of the plurality of arms comprises a first inert segment attached to the first disintegrating matrix segment, the first inert segment comprising polycaprolactone, and (BIO)2CO3.

### Claim 115 (depends on 114)

The method of claim 114, wherein each arm of the plurality of arms comprises a second disintegrating matrix segment attached to the first inert segment, the second disintegrating matrix segment comprising polycaprolactone, hydroxypropyl methylcellulose acetate succinate, and a poloxamer.

### Claim 116 (depends on 115)

The method of claim 115, wherein each arm of the plurality of arms comprises a second inert segment attached to the second disintegrating matrix segment, the second inert segment comprising polycaprolactone, and (BiO)2CO3.

### Claim 117 (depends on 116)

The method of claim 116, wherein a first arm of the plurality of arms comprises a drug-eluting component of the at least one drug-eluting component attached to the second inert segment.

### Claim 118 (depends on 117)

The method of claim 117, wherein a second arm of the plurality of arms comprises an inactive segment attached to the second inert segment, the inactive segment comprising polycaprolactone, copovidone, and a poloxamer.

### Claim 119 (depends on 117, 118)

The method of claim 117 or 118, wherein each arm of the plurality of arms comprises a third inert segment attached to one of the drug-eluting component or the inactive segment, the third inert segment comprising polycaprolactone, and (BiO)2CO3.

### Claim 120 (depends on 119)

The method of claim 119, wherein each arm of the plurality of arms comprises a third disintegrating matrix segment attached to the third inert segment, the third disintegrating matrix comprising polycaprolactone, hydroxypropyl methylcellulose acetate succinate (HPMCAS); stearic acid; and polypropylene glycol.

### Claim 121 (depends on 120)

The method of claim 120, comprising a filament circumferentially connecting each arm, wherein the circumferential filament is attached to the third disintegrating matrix segment of each arm.
